AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02461927
Drug: Placebo (psychoactive placebo midazolam) + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will receive (1) intravenous psychoactive placebo midazolam (0.045 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
Trial: NCT03470545
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral capsule
Trial: NCT01558323
Drug: LCQ908
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of LCQ908
Trial: NCT01321723
Drug: PTH analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A recombinant 1-31 amino acid fragment of PTH.
Trial: NCT01321723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02561806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01657877
Drug: Calcium sodium phosphosilicate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSP high percentage weight by weight
Trial: NCT01657877
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No CSP and no fluoride
Trial: NCT04081389
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04081389
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04081389
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00484601
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04592016
Drug: Voltaren - Diclofenac sodium gel 1% (GSK, USA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application in dermal-sampling visit
Trial: NCT04592016
Drug: Pennsaid 2 % Topical Solution (Horizon Therapeutics, USA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application in dermal-sampling visit
Trial: NCT04592016
Drug: Diclofenac sodium gel 1% (Perrigo, USA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application in dermal-sampling visit
Trial: NCT01710800
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01340040
Drug: MEDI-573
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.
Trial: NCT04064294
Drug: Intravenous Infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.
Trial: NCT01294410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks
Trial: NCT01294410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days
Trial: NCT01013740
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine
Trial: NCT01152476
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General anesthesia is maintained witn sevoflurane and remifentanil.
Trial: NCT01152476
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia is maintained with only sevoflurane and with normal saline instead of remifentanil
Trial: NCT01682746
Drug: Photofrin (porfimer sodium) & photodynamic therapy.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Photofrin~This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity \& light precautions for a minimum of 30 days after the infusion.~Photodynamic Therapy (PDT)~After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time.
Trial: NCT04169997
Drug: IMP4927
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP4297 tablet.The starting dose from 100mg QD
Trial: NCT04169997
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos tablet.The starting dose from 100mg QD
Trial: NCT00820664
Drug: Comparator: Estrace 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg tablet taken once daily for 28 days
Trial: NCT00820664
Drug: Comparator: Estrace 2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg tablets taken once daily for 28 days.
Trial: NCT00820664
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0 mg capsule taken once daily for 28 days
Trial: NCT04295330
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
Trial: NCT00642629
Drug: STA 5326 mesylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STA 5326 mesylate 100mg taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
Trial: NCT00642629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
Trial: NCT02838576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
Trial: NCT03000348
Drug: Cysteamine
RxNorm normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Cysteamine Capsule
Trial: NCT03000348
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Capsule
Trial: NCT03444844
Drug: Ga-68 P16-093 PET/CT scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection followed by PET/CT scanning
Trial: NCT00385853
Drug: PTK787/ZK 222584
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily for each 28-day cycle
Trial: NCT01719588
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Prolonged release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg every 12 hours, with or without food depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
Trial: NCT00296010
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 50 mg/day orally continuously for 16 weeks
Trial: NCT00296010
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks
Trial: NCT00296010
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)
Trial: NCT01588990
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive capecitabine 1000 mg/m\^2 per oral (PO) twice daily on Days 1-14 of 3 weeks cycle during Phase A treatment.
Trial: NCT01588990
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive leucovorin 400 mg/m\^2 IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B). Investigators may elect to chose low dose of leucovorin (either 20 mg/m\^2 or 50 mg total dose).
Trial: NCT01588990
Drug: 5-Fluouracil
RxNorm normalized name: Fluouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 5-fluouracil loading dose of 400 mg/m\^2 IV on Day 1 followed by 2400 mg/m\^2 continuous IV infusion over 46 hours Day 1 (Alternative Phase A treatment and Phase B).
Trial: NCT02500212
Drug: ENVARSUS®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02500212
Drug: ADVAGRAF®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01324479
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00346229
Drug: lyso-thermosensitive liposomal doxorubicin(Thermodox)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00781859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravitreal injection
Trial: NCT01029847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc. inj. placebo every other week, week 0, 2, and 4. Sc. inj. adalimumab 40 mg every other week from week 6.~At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.
Trial: NCT03422666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00621140
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01371734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the Placebo treatment arm will receive placebo tablets
Trial: NCT02578186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL at bedtime
Trial: NCT00461123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
Trial: NCT02710097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
Trial: NCT02710097
Drug: Active Oral Ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
Trial: NCT02710097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active cannabinoids. Administered over 20 minutes via a vaporizer.
Trial: NCT02951351
Drug: Proparacaine
RxNorm normalized name: proparacaine
DrugBank: Proparacaine (DB00807)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.
Trial: NCT01561456
Drug: AXL1717
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
Trial: NCT01965158
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken orally once a day
Trial: NCT01885013
Drug: Metformin + Myocet + Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Myocet + Cyclophosphamide:~Metformin 1000 mg, 2 times daily per os\*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~\* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day.
Trial: NCT01829893
Drug: GL2701 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral medication with 240 mL water
Trial: NCT03055546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal administration of placebo
Trial: NCT04860856
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20ml of normal saline
Trial: NCT00460317
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg QD orally every day
Trial: NCT00605566
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally.
Trial: NCT02546154
Drug: 10% Iron Isomaltoside 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard clinical practice and following the Monofer® label (SPC)
Trial: NCT03022838
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: From the point of enrollment, patients will substitute their daily dietary caffeine with either placebo- or capsulated caffeine tablets (Recip®, 100mg).
Trial: NCT00453479
Drug: GSK233705B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02104505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil capsules
Trial: NCT03912974
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see 'arm description'
Trial: NCT03486925
Drug: placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal administration of placebo
Trial: NCT00885352
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.
Trial: NCT02549417
Drug: KHK7580
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT03953456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a coated tablet for oral administration, once daily
Trial: NCT00238953
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01885013
Drug: Myocet + Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myocet + Cyclophosphamide:~Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles
Trial: NCT04486508
Drug: intermediate dose Enoxaparin/ unfractionated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose anticoagulation according to creatinine clearance and weight
Trial: NCT04486508
Drug: standard prophylactic dose Enoxaparin/ unfractionated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylaxis anticoagulation according to creatinine clearance and weight
Trial: NCT04229030
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of RZL-012 drug product
Trial: NCT03740204
Drug: 17-β estradiol transdermal patches with cyclic progesterone
RxNorm normalized name: 17α-progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 17-β estradiol transdermal patches (100 mcg 17-β estradiol/day) with cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)
Trial: NCT03740204
Drug: Placebo patch and pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch and pill
Trial: NCT04486508
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo to atorvastatin 20 mg
Trial: NCT03232710
Drug: Bosiqing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole Orally disintegrating tablets 10mg
Trial: NCT00511836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.
Trial: NCT04742062
Drug: ApTOLL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
Trial: NCT00864526
Drug: COMBONOX® tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under fasting conditions
Trial: NCT02457442
Drug: Propofol and Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High propofol and low remifentanil, changing remifentanil (up-and-down method)
Trial: NCT02457442
Drug: Propofol and Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low propofol and high remifentanil, changing propofol (up-and-down method)
Trial: NCT02457442
Drug: Sevoflurane and Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sevoflurane and low remifentanil, changing remifentanil (up-and-down method)
Trial: NCT02457442
Drug: Sevoflurane and Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sevoflurane and high remifentanil, changing sevoflurane up-and-down method)
Trial: NCT02457442
Drug: SPR2
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~Changing Sevoflurane for skin incision.
Trial: NCT02354547
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 200 mg/m² cyclophosphamide will be administered in combination with topotecan and SGT-53 IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, cyclophosphamide will be escalated to 250 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
Trial: NCT03871621
Drug: Diabetes Medicines
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-diabetic medications except SGLT2 inhibitors
Trial: NCT03177109
Drug: 5% fluoride varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically as a coating at single point in time
Trial: NCT02252458
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01397500
Drug: Testosterone undecannoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecannoate administered twice (6 week Interval) im by investigator.
Trial: NCT01085812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to be given orally, in capsule form, once daily.
Trial: NCT01168336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00003912
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03870412
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The test drug PEG-rhG-CSF was administered prophylactically to elderly lymphoma patients who met the inclusion/exclusion criteria 24-72 hours after chemotherapy.
Trial: NCT04055415
Drug: Conventional drug therapy（expectorant，bronchodilator）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug therapy（expectorant，bronchodilator）
Trial: NCT01401114
Drug: E2/LNG oral (Wellnara, BAY86-5029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis